ABT-418, a nicotinic acetylcholine receptor (nAchR) agonist, is used potentially for the treatment of attention deficit disorder.

ABT-418 hydrochloride is a selective agonist of nAChRs with cognitive enhancing and anxiolytic activities. It activates cholinergic channel and can be used for the research of Alzheimer's disease.

Epiboxidine, a methylisoxazole analog of the alkaloid Epibatidine and analog of the nAChR agonist ABT 418 [1], serves as a potent and selective agonist for neural nicotinic acetylcholine receptors (nAChR), exhibiting Ki values of 0.46 nM and 1.2 nM for rat and human α4β2 nAChRs, respectively.

Epiboxidine hydrochloride, a methylisoxazole analog of the alkaloid Epibatidine and an analog of the nAChR agonist ABT 418 [1], serves as a potent and selective agonist of neural nAChRs, demonstrating K i values of 0.46 nM and 1.2 nM for α4β2 nAChRs in rats and humans, respectively.